Differential Gene Expression Profile of Renin-Angiotensin System in the Left Atrium in Mitral Regurgitation Patients

Wen Hao Liu, Yen Nan Fang, Chia Chen Wu, Mien Cheng Chen, Jen Ping Chang, Yu Sheng Lin, Kuo Li Pan, Wan Chun Ho, Tzu Hao Chang, Yao Kuang Huang, Chih Yuan Fang, Chien Jen Chen, Wei Chieh Lee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Left atrial enlargement is a mortality and heart failure risk factor in primary mitral regurgitation (MR) patients. Pig models of MR have shown differential expression of genes linked to the renin-angiotensin system. Therefore, the aim of this study was to investigate the key genes of the renin-angiotensin that are expressed differentially in the left atrial myocardium in MR patients. Methods: Quantitative RT-PCR was used to compare gene expression in the renin-angiotensin system in the left atrium in MR patients, aortic valve disease patients, and normal subjects. Results: Plasma angiotensin II concentrations did not significantly differ between MR patients and aortic valve disease patients (P = 0.582). Compared to normal controls, however, MR patients had significantly downregulated expressions of angiotensin-converting enzyme, angiotensin I converting enzyme 2, type 1 angiotensin II receptor, glutamyl aminopeptidase, angiotensinogen, cathepsin A (CTSA), thimet oligopeptidase 1, neurolysin, alanyl aminopeptidase, cathepsin G, leucyl/cystinyl aminopeptidase (LNPEP), neprilysin, and carboxypeptidase A3 in the left atrium. The MR patients also had significantly upregulated expressions of MAS1 oncogene (MAS1) and mineralocorticoid receptor compared to normal controls. Additionally, in comparison with aortic valve disease patients, MR patients had significantly downregulated CTSA and LNPEP expression and significantly upregulated MAS1 expression in the left atrium. Conclusions: Expressions of genes in the renin-angiotensin system, especially CTSA, LNPEP, and MAS1, in the left atrium in MR patients significantly differed from expressions of these genes in aortic valve disease patients and normal controls. Notably, differences in expression were independent of circulating angiotensin II levels. The results of this study provide a rationale for pharmacological therapies or posttranslational regulation therapies targeting genes expressed differentially in the renin-angiotensin system to remedy structural remodeling associated with atrial enlargement and heart failure progression in patients with MR.

Original languageEnglish
Number of pages1
JournalDisease Markers
Volume2018
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Angiotensins
Mitral Valve Insufficiency
Renin-Angiotensin System
Heart Atria
Transcriptome
Renin
Gene expression
Cathepsin A
Genes
Peptidyl-Dipeptidase A
neurolysin
Aortic Diseases
Angiotensin II
thimet oligopeptidase
Aortic Valve
Glutamyl Aminopeptidase
Cathepsin G
CD13 Antigens
Carboxypeptidases
Mineralocorticoid Receptors

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Differential Gene Expression Profile of Renin-Angiotensin System in the Left Atrium in Mitral Regurgitation Patients. / Liu, Wen Hao; Fang, Yen Nan; Wu, Chia Chen; Chen, Mien Cheng; Chang, Jen Ping; Lin, Yu Sheng; Pan, Kuo Li; Ho, Wan Chun; Chang, Tzu Hao; Huang, Yao Kuang; Fang, Chih Yuan; Chen, Chien Jen; Lee, Wei Chieh.

In: Disease Markers, Vol. 2018, 01.01.2018.

Research output: Contribution to journalArticle

Liu, WH, Fang, YN, Wu, CC, Chen, MC, Chang, JP, Lin, YS, Pan, KL, Ho, WC, Chang, TH, Huang, YK, Fang, CY, Chen, CJ & Lee, WC 2018, 'Differential Gene Expression Profile of Renin-Angiotensin System in the Left Atrium in Mitral Regurgitation Patients', Disease Markers, vol. 2018. https://doi.org/10.1155/2018/6924608
Liu, Wen Hao ; Fang, Yen Nan ; Wu, Chia Chen ; Chen, Mien Cheng ; Chang, Jen Ping ; Lin, Yu Sheng ; Pan, Kuo Li ; Ho, Wan Chun ; Chang, Tzu Hao ; Huang, Yao Kuang ; Fang, Chih Yuan ; Chen, Chien Jen ; Lee, Wei Chieh. / Differential Gene Expression Profile of Renin-Angiotensin System in the Left Atrium in Mitral Regurgitation Patients. In: Disease Markers. 2018 ; Vol. 2018.
@article{abd25393384c4e1f8ace38231f101338,
title = "Differential Gene Expression Profile of Renin-Angiotensin System in the Left Atrium in Mitral Regurgitation Patients",
abstract = "Background: Left atrial enlargement is a mortality and heart failure risk factor in primary mitral regurgitation (MR) patients. Pig models of MR have shown differential expression of genes linked to the renin-angiotensin system. Therefore, the aim of this study was to investigate the key genes of the renin-angiotensin that are expressed differentially in the left atrial myocardium in MR patients. Methods: Quantitative RT-PCR was used to compare gene expression in the renin-angiotensin system in the left atrium in MR patients, aortic valve disease patients, and normal subjects. Results: Plasma angiotensin II concentrations did not significantly differ between MR patients and aortic valve disease patients (P = 0.582). Compared to normal controls, however, MR patients had significantly downregulated expressions of angiotensin-converting enzyme, angiotensin I converting enzyme 2, type 1 angiotensin II receptor, glutamyl aminopeptidase, angiotensinogen, cathepsin A (CTSA), thimet oligopeptidase 1, neurolysin, alanyl aminopeptidase, cathepsin G, leucyl/cystinyl aminopeptidase (LNPEP), neprilysin, and carboxypeptidase A3 in the left atrium. The MR patients also had significantly upregulated expressions of MAS1 oncogene (MAS1) and mineralocorticoid receptor compared to normal controls. Additionally, in comparison with aortic valve disease patients, MR patients had significantly downregulated CTSA and LNPEP expression and significantly upregulated MAS1 expression in the left atrium. Conclusions: Expressions of genes in the renin-angiotensin system, especially CTSA, LNPEP, and MAS1, in the left atrium in MR patients significantly differed from expressions of these genes in aortic valve disease patients and normal controls. Notably, differences in expression were independent of circulating angiotensin II levels. The results of this study provide a rationale for pharmacological therapies or posttranslational regulation therapies targeting genes expressed differentially in the renin-angiotensin system to remedy structural remodeling associated with atrial enlargement and heart failure progression in patients with MR.",
author = "Liu, {Wen Hao} and Fang, {Yen Nan} and Wu, {Chia Chen} and Chen, {Mien Cheng} and Chang, {Jen Ping} and Lin, {Yu Sheng} and Pan, {Kuo Li} and Ho, {Wan Chun} and Chang, {Tzu Hao} and Huang, {Yao Kuang} and Fang, {Chih Yuan} and Chen, {Chien Jen} and Lee, {Wei Chieh}",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/6924608",
language = "English",
volume = "2018",
journal = "Disease Markers",
issn = "0278-0240",
publisher = "IOS Press",

}

TY - JOUR

T1 - Differential Gene Expression Profile of Renin-Angiotensin System in the Left Atrium in Mitral Regurgitation Patients

AU - Liu, Wen Hao

AU - Fang, Yen Nan

AU - Wu, Chia Chen

AU - Chen, Mien Cheng

AU - Chang, Jen Ping

AU - Lin, Yu Sheng

AU - Pan, Kuo Li

AU - Ho, Wan Chun

AU - Chang, Tzu Hao

AU - Huang, Yao Kuang

AU - Fang, Chih Yuan

AU - Chen, Chien Jen

AU - Lee, Wei Chieh

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Left atrial enlargement is a mortality and heart failure risk factor in primary mitral regurgitation (MR) patients. Pig models of MR have shown differential expression of genes linked to the renin-angiotensin system. Therefore, the aim of this study was to investigate the key genes of the renin-angiotensin that are expressed differentially in the left atrial myocardium in MR patients. Methods: Quantitative RT-PCR was used to compare gene expression in the renin-angiotensin system in the left atrium in MR patients, aortic valve disease patients, and normal subjects. Results: Plasma angiotensin II concentrations did not significantly differ between MR patients and aortic valve disease patients (P = 0.582). Compared to normal controls, however, MR patients had significantly downregulated expressions of angiotensin-converting enzyme, angiotensin I converting enzyme 2, type 1 angiotensin II receptor, glutamyl aminopeptidase, angiotensinogen, cathepsin A (CTSA), thimet oligopeptidase 1, neurolysin, alanyl aminopeptidase, cathepsin G, leucyl/cystinyl aminopeptidase (LNPEP), neprilysin, and carboxypeptidase A3 in the left atrium. The MR patients also had significantly upregulated expressions of MAS1 oncogene (MAS1) and mineralocorticoid receptor compared to normal controls. Additionally, in comparison with aortic valve disease patients, MR patients had significantly downregulated CTSA and LNPEP expression and significantly upregulated MAS1 expression in the left atrium. Conclusions: Expressions of genes in the renin-angiotensin system, especially CTSA, LNPEP, and MAS1, in the left atrium in MR patients significantly differed from expressions of these genes in aortic valve disease patients and normal controls. Notably, differences in expression were independent of circulating angiotensin II levels. The results of this study provide a rationale for pharmacological therapies or posttranslational regulation therapies targeting genes expressed differentially in the renin-angiotensin system to remedy structural remodeling associated with atrial enlargement and heart failure progression in patients with MR.

AB - Background: Left atrial enlargement is a mortality and heart failure risk factor in primary mitral regurgitation (MR) patients. Pig models of MR have shown differential expression of genes linked to the renin-angiotensin system. Therefore, the aim of this study was to investigate the key genes of the renin-angiotensin that are expressed differentially in the left atrial myocardium in MR patients. Methods: Quantitative RT-PCR was used to compare gene expression in the renin-angiotensin system in the left atrium in MR patients, aortic valve disease patients, and normal subjects. Results: Plasma angiotensin II concentrations did not significantly differ between MR patients and aortic valve disease patients (P = 0.582). Compared to normal controls, however, MR patients had significantly downregulated expressions of angiotensin-converting enzyme, angiotensin I converting enzyme 2, type 1 angiotensin II receptor, glutamyl aminopeptidase, angiotensinogen, cathepsin A (CTSA), thimet oligopeptidase 1, neurolysin, alanyl aminopeptidase, cathepsin G, leucyl/cystinyl aminopeptidase (LNPEP), neprilysin, and carboxypeptidase A3 in the left atrium. The MR patients also had significantly upregulated expressions of MAS1 oncogene (MAS1) and mineralocorticoid receptor compared to normal controls. Additionally, in comparison with aortic valve disease patients, MR patients had significantly downregulated CTSA and LNPEP expression and significantly upregulated MAS1 expression in the left atrium. Conclusions: Expressions of genes in the renin-angiotensin system, especially CTSA, LNPEP, and MAS1, in the left atrium in MR patients significantly differed from expressions of these genes in aortic valve disease patients and normal controls. Notably, differences in expression were independent of circulating angiotensin II levels. The results of this study provide a rationale for pharmacological therapies or posttranslational regulation therapies targeting genes expressed differentially in the renin-angiotensin system to remedy structural remodeling associated with atrial enlargement and heart failure progression in patients with MR.

UR - http://www.scopus.com/inward/record.url?scp=85058910595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058910595&partnerID=8YFLogxK

U2 - 10.1155/2018/6924608

DO - 10.1155/2018/6924608

M3 - Article

VL - 2018

JO - Disease Markers

JF - Disease Markers

SN - 0278-0240

ER -